


PHARMACEUTICAL 2021

MACROGENICS INC Rank 177 of 409









PHARMACEUTICAL 2021

MACROGENICS INC Rank 177 of 409



The relative strengths and weaknesses of MACROGENICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MACROGENICS INC compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 88% points. The greatest weakness of MACROGENICS INC is the variable Research and Development, reducing the Economic Capital Ratio by 159% points.

The company's Economic Capital Ratio, given in the ranking table, is -87%, being 267% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	312,594
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	50,673
Liabilities, Non-Current	25,260
Other Assets	23,924
Other Compr. Net Income	-23
Other Expenses	0
Other Liabilities	6,926
Other Net Income	1,321
Property and Equipment	42,225
Research and Development	193,201
Revenues	104,883
Selling, General and Administrative Expense	42,742

Output Variable	Value in 1000 USD
Assets	378,743
Liabilities	82,859
Expenses	235,943
Stockholders Equity	295,884
Net Income	-129,739
Comprehensive Net Income	-129,750
Economic Capital Ratio	-87%

